IL267856A - Compositions comprising a bifunctional protein targeting pd-l1 and tgfb - Google Patents

Compositions comprising a bifunctional protein targeting pd-l1 and tgfb

Info

Publication number
IL267856A
IL267856A IL267856A IL26785619A IL267856A IL 267856 A IL267856 A IL 267856A IL 267856 A IL267856 A IL 267856A IL 26785619 A IL26785619 A IL 26785619A IL 267856 A IL267856 A IL 267856A
Authority
IL
Israel
Prior art keywords
tgfb
compositions
bifunctional protein
protein targeting
targeting
Prior art date
Application number
IL267856A
Other languages
English (en)
Hebrew (he)
Inventor
Bawab Samer El
Yulia Vugmeyster
Akash Khandelwal
Isabelle Dussault
Original Assignee
Merck Patent Gmbh
Bawab Samer El
Yulia Vugmeyster
Akash Khandelwal
Isabelle Dussault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Bawab Samer El, Yulia Vugmeyster, Akash Khandelwal, Isabelle Dussault filed Critical Merck Patent Gmbh
Publication of IL267856A publication Critical patent/IL267856A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endoscopes (AREA)
IL267856A 2017-01-07 2019-07-04 Compositions comprising a bifunctional protein targeting pd-l1 and tgfb IL267856A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443698P 2017-01-07 2017-01-07
US201762581978P 2017-11-06 2017-11-06
PCT/US2018/012604 WO2018129331A1 (en) 2017-01-07 2018-01-05 Dosing regimens and dosage forms for targeted tgf-b inhibition

Publications (1)

Publication Number Publication Date
IL267856A true IL267856A (en) 2019-09-26

Family

ID=62791283

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267856A IL267856A (en) 2017-01-07 2019-07-04 Compositions comprising a bifunctional protein targeting pd-l1 and tgfb

Country Status (15)

Country Link
US (1) US20190330375A1 (enExample)
EP (1) EP3565599A4 (enExample)
JP (1) JP2020514290A (enExample)
KR (1) KR20190102059A (enExample)
CN (1) CN110198738A (enExample)
AU (1) AU2018205233A1 (enExample)
BR (1) BR112019013924A2 (enExample)
CA (1) CA3048646A1 (enExample)
CL (1) CL2019001871A1 (enExample)
IL (1) IL267856A (enExample)
MX (1) MX2019008001A (enExample)
PH (1) PH12019501574A1 (enExample)
RU (1) RU2019124875A (enExample)
SG (1) SG11201906157YA (enExample)
WO (1) WO2018129331A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
SI3628049T1 (sl) 2017-05-04 2023-10-30 Acceleron Pharma Inc. Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba
AU2019288765A1 (en) * 2018-06-22 2021-01-07 Merck Patent Gmbh Dosing regimens for targeted TGF-β inhibition for use in treating biliary tract cancer
BR112020026902A2 (pt) * 2018-07-02 2021-03-30 Merck Patent Gmbh Terapia combinada com inibição direcionada de tgf-b para o tratamento de câncer de pulmão de células não pequenas avançado
SG11202100208VA (en) 2018-07-09 2021-02-25 Precigen Inc Fusion constructs and methods of using thereof
JP7436477B2 (ja) * 2018-11-09 2024-02-21 ジエンス ヘンルイ メデイシンカンパニー リミテッド ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用
MX2021009175A (es) 2019-01-30 2021-09-14 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
AU2020290119B2 (en) * 2019-06-10 2024-07-18 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PDL1 and TGFβ and use thereof
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
WO2021081321A1 (en) * 2019-10-24 2021-04-29 Amgen Inc. Systems and approaches for drug delivery
WO2021084124A1 (en) * 2019-11-01 2021-05-06 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
EP4054617A4 (en) * 2019-11-05 2023-12-27 Acceleron Pharma Inc. Treatments for systemic sclerosis
US20230035169A1 (en) * 2019-12-11 2023-02-02 WuXi Biologics Ireland Limited BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGF-Beta
CN115135302A (zh) * 2019-12-20 2022-09-30 阿雷斯贸易股份有限公司 IgG:TGFβRII融合蛋白组合物
CN111118064B (zh) * 2019-12-24 2022-10-25 华南理工大学 一种精子生成障碍动物模型及其制备方法与应用
MX2022008609A (es) 2020-01-11 2022-11-10 Scholar Rock Inc Inhibidores de tgf¿ y uso de los mismos.
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
CN115135675A (zh) * 2020-02-18 2022-09-30 南京金斯瑞生物科技有限公司 融合蛋白及其用途
EP4093779A4 (en) * 2020-02-25 2024-03-06 Wuxi Biologics Ireland Limited BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
CN116323657B (zh) * 2020-09-24 2023-12-08 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
US20240148903A1 (en) 2021-03-08 2024-05-09 Nanjing GenScript Biotech Co., Ltd. Delivery of antibody by using dual viral vector system
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3231649A1 (en) * 2021-11-19 2023-05-25 Cecilia Anna Wilhelmina Geuijen Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785682A (en) * 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
JP6066732B2 (ja) * 2010-03-05 2017-01-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
US20130110045A1 (en) * 2011-10-31 2013-05-02 Ming-Yuan Wu Single use intravenous therapy administering device with needle safety covers
PT3489254T (pt) * 2012-04-30 2022-12-30 Biocon Ltd Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
SI3105246T1 (sl) * 2014-02-10 2021-11-30 Merck Patent Gmbh Ciljana inhibicija TGF BETA
CN114920840A (zh) * 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CA2975147C (en) * 2015-01-31 2025-06-10 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS
EP3277716B1 (en) * 2015-04-03 2020-06-24 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
MX2017014381A (es) * 2015-05-12 2018-03-02 Genentech Inc Metodos terapeuticos y diagnosticos para cancer.

Also Published As

Publication number Publication date
CL2019001871A1 (es) 2019-12-13
RU2019124875A3 (enExample) 2021-07-08
EP3565599A4 (en) 2020-07-01
AU2018205233A1 (en) 2019-07-11
PH12019501574A1 (en) 2019-11-04
BR112019013924A2 (pt) 2020-02-11
US20190330375A1 (en) 2019-10-31
KR20190102059A (ko) 2019-09-02
CA3048646A1 (en) 2018-07-12
SG11201906157YA (en) 2019-08-27
RU2019124875A (ru) 2021-02-08
WO2018129331A1 (en) 2018-07-12
MX2019008001A (es) 2019-09-09
CN110198738A (zh) 2019-09-03
JP2020514290A (ja) 2020-05-21
EP3565599A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
IL267856A (en) Compositions comprising a bifunctional protein targeting pd-l1 and tgfb
ZA202003833B (en) Conjugates and preparation and use thereof
SG11202001208XA (en) Rna targeting methods and compositions
IL268828B2 (en) Products and compositions
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
IL286847A (en) hsp90-binding couplers and formulations thereof
IL250711A0 (en) Conjugates containing cell-binding agents and cytotoxic agents
IL277542A (en) CD22-targeting constructs and uses thereof
LT3603620T (lt) Liposomų kompozicija ir farmacinė kompozicija
EP3324967A4 (en) PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
SG11201708674XA (en) Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof
CA3247217A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
IL277791A (en) HSP90 targeting conjugates and their formulations
IL269576A (en) products and vehicles
EP3668838A4 (en) TETRAMALEIMIDE NETWORKER AND USES THEREOF
PT3638251T (pt) Formulações de gel de bifosfocina e suas utilizações
IL269517A (en) compounds and products
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
GB202002129D0 (en) stable freshening compositions and products comprising the same
SG11202009734VA (en) Integrin targeting ligands and uses thereof
IL272164B1 (en) 3-Acyl-benzamides and their use as herbicides
SG11202012763TA (en) Ivosidenib forms and pharmaceutical compositions
EP3635324A4 (en) REVERSE FREEZING COMPOSITIONS AND USE OF THEM
HK40038485A (en) Hsp90-targeting conjugates and formulations thereof
HK40036554A (en) Sstr-targeted conjugates and formulations thereof